NCT04307979 is a NA clinical trial of High-fat coffee in Leukocytosis, sponsored by University of British Columbia.

Who is sponsoring NCT04307979?

NCT04307979 is sponsored by University of British Columbia.

What drugs are being tested in NCT04307979?

Interventions in NCT04307979: High-fat coffee, Black coffee.

What condition does NCT04307979 study?

NCT04307979 studies Leukocytosis, Triglycerides, Cognitive Function, Inflammatory Response.

Is NCT04307979 still recruiting?

NCT04307979 is currently status unknown. Last updated 13 March 2020.

Last reviewed 2020-03-13 · How we verify

NCT04307979

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute High Fat Bulletproof Coffee vs Black Coffee on Metabolism, Inflammation and Cognitive Function in Healthy Adults

Status unknown NA Last updated 13 March 2020

What this trial tests

NA trial testing High-fat coffee in Leukocytosis in 20 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	University of British Columbia
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Enrollment	20
Start date	1 January 2020
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Canada

Drugs / interventions tested

High-fat coffee
Black coffee

Conditions studied

Leukocytosis — all drugs for Leukocytosis →
Triglycerides — all drugs for Triglycerides →
Cognitive Function — all drugs for Cognitive Function →
Inflammatory Response — all drugs for Inflammatory Response →

Sponsor

University of British Columbia

Who can join

Adults 18 to 55, any sex, with Leukocytosis or Triglycerides. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will determine whether acute ingestion of a high fat "Bulletproof Coffee" will lead to changes in plasma triglycerides, immune cell function, as well as cognitive function when compared to a black coffee.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of British Columbia trials

Trials by the same sponsor.

NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04307979 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 13 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04307979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing